Expect patent-heavy pharma acquisitions following Novartis’ $13 billion consumer healthcare divestment

This week saw the headline-grabbing multi-billion dollar sell-off by Novartis of its consumer healthcare business. Reflecting the Swiss entity’s desire to focus resources on strengthening its position in higher-priority therapeutic spaces, the deal…